The resurgence of psychedelic medicine faces a critical inflection point as regulatory realities clash with therapeutic promises. Despite hundreds of ongoing studies examining compounds like MDMA, psilocybin, and LSD for psychiatric conditions, no psychedelic treatments have gained FDA approval, and MDMA's recent rejection signals broader challenges ahead for the entire field. The core dilemma centers on whether the distinctive altered consciousness induced by psychedelics is therapeutically essential or merely an unwanted side effect. This fundamental question undermines traditional clinical trial methodology, since patients inevitably know when they've received an active psychedelic versus placebo, making proper blinding nearly impossible. The FDA's concerns about MDMA trials—including inadequate blinding, therapist bias, and insufficient safety data—apply equally to classical psychedelics now in development. Compounding these scientific challenges are evolving social attitudes, with some jurisdictions decriminalizing or legalizing psychedelic use outside medical contexts. This regulatory patchwork creates uncertainty for pharmaceutical companies investing in controlled clinical development. The field must navigate whether pharmacologically-assisted psychotherapy represents a fundamentally new treatment paradigm requiring different regulatory frameworks, or whether existing drug approval standards can accommodate these unique therapeutic mechanisms. Success may depend on identifying patient populations where psychedelic effects provide clear, measurable benefits that outweigh the inherent trial design limitations. The therapeutic potential remains compelling, but the path from promising early studies to approved medicines appears more complex than initially anticipated.